Navigation Links
InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference
Date:9/4/2008

FORT COLLINS, Colo., Sept. 4 /PRNewswire/ -- InVitria (http://www.invitria.com), a leading global supplier of animal free products that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry, announced its Sponsorship of Cambridge Healthtech Institute's 4th Annual "Optimizing Cell Culture Development" Conference on September 15-16 in Boston, Massachusetts. (http://www.healthtech.com/ocb/overview.aspx?c=562)

InVitria will be an exhibitor at the conference, which will feature notable speakers from research and development institutes and the biotech industry. The meeting sessions focus on cell line development, cell engineering, upstream processing and scale-up & manufacturing of products derived from cell culture.

"InVitria is very pleased to serve as one of the corporate sponsors for this event for the cell culture industry," said Scott Deeter, InVitria's president. "We feel this is a tremendous venue to build awareness of how InVitria's animal free products available for use in cell culture media help improve productivity, safety and time to market for our customers."

"InVitria's Cellastim and Lacromin not only replace bovine or human sources of albumin or transferrin, but they also provide improved productivity and better consistency," said Ray Tritch, InVitria's Account Manager - Eastern United States. "I am looking forward to sharing our successful results using these cell culture ingredients to optimize performance," Tritch said.

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim -- Cellastim is an albumin used to replace bovine albumin and human albumin as a cell culture ingredient and biopharmaceutical formulation excipient. Cellastim has been shown to improve mammalian cell culture productivity by up to 50% when compared with other forms of albumin. Cellastim also has been an effective component in stem cell media and primary cell media. (see http://www.Cellastim.com )

-- Lacromin -- Lacromin has been shown to replace bovine transferrin and human transferrin in cell culture media. In addition, Lacromin is a strong growth promotant as a cell culture ingredient in mammalian cell culture media. (see http://www.Lacromin.com )

-- Lysobac -- Lysobac is a bacterial cell lysis agent that is more efficient and more consistent compared to chicken lysozyme and provides higher protein yield compared with mechanical cell lysis. Lysobac is used in bacterial fermentation to improve recombinant protein yields. (see http://www.Lysobac.com )

For more information about the InVitria line of products, please e-mail info@invitria.com or call 1-800-916-8311.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
2. InVitria Expands Sales Team
3. InVitrias Animal Free Lacromin(TM) Provides a Cost-Effective Improvement Over Transferrin
4. TCN e-Systems Offers Trial Sponsors Solutions for Creating In-House Center of Excellence in Patient Recruitment
5. BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008
6. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
7. Baxa Announces Colorado BioScience Association Sponsorship
8. Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer
9. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
10. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
11. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):